Kristen L Jablonski1, Olga V Fedorova, Matthew L Racine, Candace J Geolfos, Phillip E Gates, Michel Chonchol, Bradley S Fleenor, Edward G Lakatta, Alexei Y Bagrov, Douglas R Seals. 1. Department of Integrative Physiology, University of Colorado Boulder, Boulder, Colorado;, †Intramural Research Program, Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, Maryland;, ‡Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, United Kingdom, §Division of Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Center, Aurora, Colorado.
Abstract
BACKGROUND AND OBJECTIVES:Systolic BP and large elastic artery stiffness both increase with age and are reduced by dietary sodium restriction. Production of the natriuretic hormone marinobufagenin, an endogenous α1 Na+,K+-ATPase inhibitor, is increased in salt-sensitive hypertension and contributes to the rise in systolic BP during sodium loading. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The hypothesis was that dietary sodium restriction performed in middle-aged/older adults (eight men and three women; 60 ± 2 years) with moderately elevated systolic BP (139 ± 2/83 ± 2 mmHg) would reduce urinary marinobufagenin excretion as well as systolic BP and aortic pulse-wave velocity (randomized, placebo-controlled, and crossover design). This study also explored the associations among marinobufagenin excretion with systolic BP and aortic pulse-wave velocity across conditions of 5 weeks of a low-sodium (77 ± 9 mmol/d) and 5 weeks of a normal-sodium (144 ± 7 mmol/d) diet. RESULTS:Urinary marinobufagenin excretion (weekly measurements; 25.4 ± 1.8 versus 30.7 ± 2.1 pmol/kg per day), systolic BP (127 ± 3 versus 138 ± 5 mmHg), and aortic pulse-wave velocity (700 ± 40 versus 843 ± 36 cm/s) were lower during the low- versus normal-sodium condition (all P<0.05). Across all weeks, marinobufagenin excretion was related with systolic BP (slope=0.61, P<0.001) and sodium excretion (slope=0.46, P<0.001). These associations persisted during the normal- but not the low-sodium condition (both P<0.005). Marinobufagenin excretion also was associated with aortic pulse-wave velocity (slope=0.70, P=0.02) and endothelial cell expression of NAD(P)H oxidase-p47phox (slope=0.64, P=0.006). CONCLUSIONS: These results show, for the first time in humans, that dietary sodium restriction reduces urinary marinobufagenin excretion and that urinary marinobufagenin excretion is positively associated with systolic BP, aortic stiffness (aortic pulse-wave velocity), and endothelial cell expression of the oxidant enzyme NAD(P)H oxidase. Importantly, marinobufagenin excretion is positively related to systolic BP over ranges of sodium intake typical of an American diet, extending previous observations in rodents and humans fed experimentally high-sodium diets.
RCT Entities:
BACKGROUND AND OBJECTIVES: Systolic BP and large elastic artery stiffness both increase with age and are reduced by dietary sodium restriction. Production of the natriuretic hormone marinobufagenin, an endogenous α1 Na+,K+-ATPase inhibitor, is increased in salt-sensitive hypertension and contributes to the rise in systolic BP during sodium loading. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The hypothesis was that dietary sodium restriction performed in middle-aged/older adults (eight men and three women; 60 ± 2 years) with moderately elevated systolic BP (139 ± 2/83 ± 2 mmHg) would reduce urinary marinobufagenin excretion as well as systolic BP and aortic pulse-wave velocity (randomized, placebo-controlled, and crossover design). This study also explored the associations among marinobufagenin excretion with systolic BP and aortic pulse-wave velocity across conditions of 5 weeks of a low-sodium (77 ± 9 mmol/d) and 5 weeks of a normal-sodium (144 ± 7 mmol/d) diet. RESULTS: Urinary marinobufagenin excretion (weekly measurements; 25.4 ± 1.8 versus 30.7 ± 2.1 pmol/kg per day), systolic BP (127 ± 3 versus 138 ± 5 mmHg), and aortic pulse-wave velocity (700 ± 40 versus 843 ± 36 cm/s) were lower during the low- versus normal-sodium condition (all P<0.05). Across all weeks, marinobufagenin excretion was related with systolic BP (slope=0.61, P<0.001) and sodium excretion (slope=0.46, P<0.001). These associations persisted during the normal- but not the low-sodium condition (both P<0.005). Marinobufagenin excretion also was associated with aortic pulse-wave velocity (slope=0.70, P=0.02) and endothelial cell expression of NAD(P)H oxidase-p47phox (slope=0.64, P=0.006). CONCLUSIONS: These results show, for the first time in humans, that dietary sodium restriction reduces urinary marinobufagenin excretion and that urinary marinobufagenin excretion is positively associated with systolic BP, aortic stiffness (aortic pulse-wave velocity), and endothelial cell expression of the oxidant enzyme NAD(P)H oxidase. Importantly, marinobufagenin excretion is positively related to systolic BP over ranges of sodium intake typical of an American diet, extending previous observations in rodents and humans fed experimentally high-sodium diets.
Authors: Lawrence J Appel; Edward D Frohlich; John E Hall; Thomas A Pearson; Ralph L Sacco; Douglas R Seals; Frank M Sacks; Sidney C Smith; Dorothea K Vafiadis; Linda V Van Horn Journal: Circulation Date: 2011-01-13 Impact factor: 29.690
Authors: Michel E Safar; Jacques Blacher; Bruno Pannier; Alain P Guerin; Sylvain J Marchais; Pierre-Marie Guyonvarc'h; Gérard M London Journal: Hypertension Date: 2002-03-01 Impact factor: 10.190
Authors: Anthony J Donato; Alexander D Black; Kristen L Jablonski; Lindsey B Gano; Douglas R Seals Journal: Aging Cell Date: 2008-09-08 Impact factor: 9.304
Authors: Kristen L Jablonski; Jelena Klawitter; Michel Chonchol; Candace J Bassett; Matthew L Racine; Douglas R Seals Journal: Clin J Am Soc Nephrol Date: 2015-04-21 Impact factor: 8.237
Authors: J Kato; Y Kawagoe; D Jiang; K Kuwasako; S Shimamoto; K Igarashi; M Tokashiki; K Kitamura Journal: J Hum Hypertens Date: 2017-03-02 Impact factor: 3.012
Authors: Kristen L Nowak; Michel Chonchol; Anna Jovanovich; Zhiying You; Jeffrey Bates; Capri Foy; Stephen Glasser; Anthony A Killeen; John Kostis; Carlos J Rodriguez; Mark Segal; Debra L Simmons; Addison Taylor; Laura C Lovato; Walter T Ambrosius; Mark A Supiano Journal: Am J Hypertens Date: 2019-06-11 Impact factor: 2.689
Authors: Igor V Emelyanov; Alexandra O Konradi; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov Journal: Curr Top Membr Date: 2019-02-18 Impact factor: 3.049
Authors: Kristen L Jablonski; Anthony J Donato; Bradley S Fleenor; Molly J Nowlan; Ashley E Walker; Rachelle E Kaplon; Dov B Ballak; Douglas R Seals Journal: J Hypertens Date: 2015-12 Impact factor: 4.844